

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
7 April 2011 (07.04.2011)

(10) International Publication Number
WO 2011/041146 A2

PCT

(51) International Patent Classification:
A61K 31/137 (2006.01)

BioMedical Research Inc., 220 Massachusetts Avenue,
Cambridge, MA 02139 (US).

(21) International Application Number:
PCT/US2010/049441

(74) Agent: **HOUGHTON, Gregory C.**; Novartis, Patent Department, One Health Plaza, Bldg. 101, East Hanover, NJ 07936-1080 (US).

(22) International Filing Date:
20 September 2010 (20.09.2010)

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/246,706 29 September 2009 (29.09.2009) US
61/258,329 5 November 2009 (05.11.2009) US
61/307,992 25 February 2010 (25.02.2010) US
61/352,029 7 June 2010 (07.06.2010) US

(71) Applicant (*for all designated States except US*): **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **BOULTON, Craig** [GB/GB]; Novartis Pharmaceuticals UK Limited, Wimbleshurst Road, Horsham, West Essex RH 12 5AB (GB). **BURTIN, Pascale** [FR/CH]; Novartis Pharma AG, Postfach 4002, CH-4002 Basel (CH). **DAVID, Olivier** [FR/CH]; Novartis Pharma AG, Postfach 4002, CH-4002 Basel (CH). **DE VERA, Ana** [ES/CH]; Novartis Pharma AG, Postfach 4002, CH-4002 Basel (CH). **DUMORTIER, Thomas** [BE/CH]; Novartis Pharma AG, Postfach 4002, CH-4002 Basel (CH). **HUNT, Irene** [US/CH]; Novartis Pharma AG, Postfach 4002, CH-4002 Basel (CH). **SCHMOUDER, Robert** [US/US]; Novartis Institutes for

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*

(54) Title: DOSAGE REGIMEN OF AN S1P RECEPTOR MODULATOR

(57) Abstract: S1P receptor modulators are administered following a dosage regimen providing a positive benefit-risk profile.



WO 2011/041146 A2